Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2004 1
2009 1
2010 1
2011 2
2012 1
2021 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Practical Recommendations for Optimal Thromboprophylaxis in Patients with COVID-19: A Consensus Statement Based on Available Clinical Trials.
Kyriakoulis KG, Dimakakos E, Kyriakoulis IG, Catalano M, Spyropoulos AC, Schulman S, Douketis J, Falanga A, Maraveyas A, Olinic DM, Belch J, Gerotziafas G, Syrigos K, Kollias A; COVID-19 Thrombosis Collaborative Group, Endorsed by VAS-European Independent Foundation in Angiology/Vascular Medicine, UEMS Division of Angiology/Vascular Medicine/and ESVM-European Society of Vascular Medicine and Supported by the Balkan Working Group. Kyriakoulis KG, et al. J Clin Med. 2022 Oct 11;11(20):5997. doi: 10.3390/jcm11205997. J Clin Med. 2022. PMID: 36294316 Free PMC article. Review.
Rituximab for idiopathic membranous nephropathy.
Remuzzi G, Chiurchiu C, Abbate M, Brusegan V, Bontempelli M, Ruggenenti P. Remuzzi G, et al. Among authors: brusegan v. Lancet. 2002 Sep 21;360(9337):923-4. doi: 10.1016/S0140-6736(02)11042-7. Lancet. 2002. PMID: 12354476 Clinical Trial.
Preventing microalbuminuria in type 2 diabetes.
Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, Rubis N, Gherardi G, Arnoldi F, Ganeva M, Ene-Iordache B, Gaspari F, Perna A, Bossi A, Trevisan R, Dodesini AR, Remuzzi G; Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. Ruggenenti P, et al. Among authors: brusegan v. N Engl J Med. 2004 Nov 4;351(19):1941-51. doi: 10.1056/NEJMoa042167. Epub 2004 Oct 31. N Engl J Med. 2004. PMID: 15516697 Free article. Clinical Trial.
Measurable urinary albumin predicts cardiovascular risk among normoalbuminuric patients with type 2 diabetes.
Ruggenenti P, Porrini E, Motterlini N, Perna A, Ilieva AP, Iliev IP, Dodesini AR, Trevisan R, Bossi A, Sampietro G, Capitoni E, Gaspari F, Rubis N, Ene-Iordache B, Remuzzi G; BENEDICT Study Investigators. Ruggenenti P, et al. J Am Soc Nephrol. 2012 Oct;23(10):1717-24. doi: 10.1681/ASN.2012030252. Epub 2012 Aug 30. J Am Soc Nephrol. 2012. PMID: 22935482 Free PMC article. Clinical Trial.
Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial.
Ruggenenti P, Fassi A, Ilieva A, Iliev IP, Chiurchiu C, Rubis N, Gherardi G, Ene-Iordache B, Gaspari F, Perna A, Cravedi P, Bossi A, Trevisan R, Motterlini N, Remuzzi G; BENEDICT-B Study Investigators. Ruggenenti P, et al. J Hypertens. 2011 Feb;29(2):207-16. doi: 10.1097/hjh.0b013e32834069bd. J Hypertens. 2011. PMID: 21243736 Clinical Trial.
Effects of manidipine and delapril in hypertensive patients with type 2 diabetes mellitus: the delapril and manidipine for nephroprotection in diabetes (DEMAND) randomized clinical trial.
Ruggenenti P, Lauria G, Iliev IP, Fassi A, Ilieva AP, Rota S, Chiurchiu C, Barlovic DP, Sghirlanzoni A, Lombardi R, Penza P, Cavaletti G, Piatti ML, Frigeni B, Filipponi M, Rubis N, Noris G, Motterlini N, Ene-Iordache B, Gaspari F, Perna A, Zaletel J, Bossi A, Dodesini AR, Trevisan R, Remuzzi G; DEMAND Study Investigators. Ruggenenti P, et al. Hypertension. 2011 Nov;58(5):776-83. doi: 10.1161/HYPERTENSIONAHA.111.174474. Epub 2011 Sep 19. Hypertension. 2011. PMID: 21931073 Clinical Trial.